GlassScriptPhysician profile
Jason Thomason
NPI 1760080824
$1,864.25
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.52 · 2021: $1,186 · 2022: $640.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $421.79 | 2021-2022 | |
| Alcon Vision LLC | $234.31 | 2020-2022 | |
| Glaukos Corporation | $229.47 | 2021 | |
| Sun Pharmaceutical Industries INC. | $178.22 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $169.62 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.03 | 2020-2021 | |
| Coopervision INC. | $118.47 | 2021 | |
| Horizon Therapeutics Plc | $114.32 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $111.81 | 2021 | |
| Allergan, INC. | $80.41 | 2022 | |
| Oyster Point Pharma, INC. | $66.80 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.